Vedanta's $60M Lifeline: What VE303 Must Prove in C. diff Phase 3

Vedanta Biosciences raised $60M, including $20M from BARDA, to finish the Phase 3 that decides its microbiome bet on VE303 in recurrent C. difficile infection. Plus Replimune's Tudriqev wins accelerated FDA approval in advanced melanoma after two rejections, LifeMine Therapeutics raises $263M for a fungal-derived calcineurin inhibitor in organ transplant, Revolution Medicines reports more than 2,000 compassionate use prescriptions for pancreatic cancer drug daraxonrasib, and Insmed lifts Brinsupri guidance after a record quarter. Visit us at thepharmacloseout.com.